Israeli biotech Gamida has successfully transplanted just its manipulated NiCord stem cells into patients with blood cancer. The impact is to reduce recovery times even further from the two years achieved from using NiCord combined with non-manipulated stem cells. http://www.globes.co.il/serveen/globes/docview.asp?did=1000878214&fid=1725 … Continue reading →

(Thanks to Atid-EDI) Early trials of NiCord (umbilical cord stem cells) from Israel’s Gamida Cell have proved successful in maintaining the health of patients with high-risk hematological malignancies. The treatment was safe and reduced the time to recovery period. http://www.gamida-cell.com/press_item.asp?ID=54

Israel’s Gamida Cell Ltd. reported success in the Phase III clinical trial of its StemEx treatment for leukemia and lymphoma. Compared to a control group, far more patients receiving StemEx survived 100 days or more following transplantation. http://www.gamida-cell.com/press_item.asp?ID=53

Israel’s Teva and Gamida Cell Ltd have completed enrolment of patients for their Phase III clinical trial of StemEx, a cell therapy for the treatment of leukemia and lymphoma. StemEx is for adolescents and adults who cannot find family-related, matched … Continue reading →